سعر بنداموستين-اكورد 25 مجم 5 فيال 2026

Bendamustine hydrochloride 25 mg powder for concentrate for solution for IV infusion; Egyptian Bendamustine-Accord (5 vials × 25 mg).

• First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) when fludarabine combination chemotherapy is not appropriatePopulation: AdultsUK eMC / MHRA SmPC
• Indolent non-Hodgkin lymphomas as monotherapy in patients who progressed during or within 6 months after rituximab or a rituximab-containing regimenPopulation: AdultsUK eMC / MHRA SmPC
• Front-line multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone when autologous stem cell transplantation and thalidomide or bortezomib-containing therapy are not appropriate (age >65 years)Population: Adults >65 years (per UK SmPC criteria)UK eMC / MHRA SmPC

• Very common/common (UK SmPC class effects): myelosuppression (leukopenia, thrombocytopenia, anaemia), infections, nausea, vomiting, mucositis, fatigue, fever, rash.International label, same formulation · UK eMC / MHRA SmPC

• Hypersensitivity to bendamustine hydrochloride or any excipient.International label, same formulation · UK eMC / MHRA SmPC
• Breast-feeding; severe hepatic impairment (serum bilirubin > 3.0 mg/dl); jaundice; severe bone marrow suppression (leukocytes < 3,000/µl or platelets < 75,000/µl); major surgery < 30 days before start; infections especially with leukocytopenia; yellow fever vaccination.International label, same formulation · UK eMC / MHRA SmPC

• Myelosuppression is dose-limiting; monitor blood counts. Infections, skin reactions, infusion reactions, tumour lysis syndrome, and secondary malignancies have been reported. Hepatotoxicity and cardiac effects possible.International label, same formulation · UK eMC / MHRA SmPC
• US label (DailyMed bendamustine): myelosuppression, infections, anaphylaxis/infusion reactions, tumour lysis syndrome, skin reactions including SJS/TEN, hepatotoxicity, other malignancies, extravasation injury.International label, same formulation · DailyMed (NLM)

• CYP1A2 inhibitors/inducersModerateBendamustine is metabolised via CYP1A2; caution with strong CYP1A2 inhibitors or inducers (UK SmPC).UK eMC / MHRA SmPC

• Bendamustine is teratogenic and mutagenic; contraindicated in pregnancy unless clearly necessary. Women of childbearing potential and men must use effective contraception during and after treatment (per SmPC timelines).International label, same formulation · UK eMC / MHRA SmPC
• Contraindicated during breast-feeding (UK SmPC).International label, same formulation · UK eMC / MHRA SmPC

• Bendamustine hydrochloride: Forms electrophilic alkyl groups causing DNA cross-links and strand breaks leading to cell death.